Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 6, 2025
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
GlobeNewswire
·
May 6, 2025
WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates. “The …
SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025
GlobeNewswire
·
May 6, 2025
SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare …
Supernus Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024. First quarter 2025 total revenues …
Pennant Reports First Quarter 2025 Results
GlobeNewswire
·
May 6, 2025
EAGLE, Idaho, May 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted …
LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance
GlobeNewswire
·
May 6, 2025
Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70% Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago period Telehealth adjusted EBITDA increased to $5.3 million from a loss of $1.3 million …
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 6, 2025
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude’s once daily, oral SMARCA2 degrader, PRT7732 is …
89bio to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 6, 2025
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
GlobeNewswire
·
May 6, 2025
Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year. First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue …
Amwell makes grant to new employee under inducement plan
GlobeNewswire
·
May 6, 2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading technology-enabled care platform provider, announced that on May 6, Amwell made a grant of RSUs of 3,451 shares of its Class A common stock to one new employee. The grant was offered …
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
GlobeNewswire
·
May 6, 2025
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to …
InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2025
GlobeNewswire
·
May 6, 2025
DENVER, May 06, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All- …
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance
GlobeNewswire
·
May 6, 2025
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-year First quarter 2025 Total revenues of $462 million, up 33% year-over-year Medicare Advantage medical costs are in line with expectations, underscoring the strength of Clover’ …
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
GlobeNewswire
·
May 6, 2025
IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its …
WW International, Inc. Announces First Quarter 2025 Results
GlobeNewswire
·
May 6, 2025
Total End of Period Subscribers of 3.4 million, including 135 thousand End of Period Clinical Subscribers Revenues of $186.6 million, down 9.7% vs. prior year period, including Clinical Subscription Revenues of $29.5 million, up 57.1% vs. prior year period …
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients …
Voyager Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 6, 2025
– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ …
Lantheus Announces Sale of SPECT Business to SHINE Technologies
GlobeNewswire
·
May 6, 2025
Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite® BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus …
Standard BioTools Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 …
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 6, 2025
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an …
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
GlobeNewswire
·
May 6, 2025
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation …